Virtual Library

Start Your Search

M. Hellmann



Author of

  • +

    Best abstracts selected from submissions 6 (ID 7)

    • Event: ACLC 2018
    • Type: Oral Session
    • Track:
    • Presentations: 1
    • +

      OA11 - First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (?10 mut/Mb): Results From CheckMate 227 (ID 166)

      16:20 - 17:00  |  Author(s): M. Hellmann

      • Abstract
      • Slides

      Background:
      CheckMate 227 (NCT02477826), a randomized, open-label, multipart, phase 3 study, demonstrated significant progression-free survival (PFS) benefit with first-line nivolumab + ipilimumab versus histology-based, platinum-doublet chemotherapy (PT-DC) in patients with advanced non-small cell lung cancer (NSCLC) and high tumor mutational burden (TMB; ?10 mutations/megabase [mut/Mb]). Safety was manageable and consistent with prior reports for nivolumab + low-dose ipilimumab. Here we report efficacy and safety of nivolumab + ipilimumab versus PT-DC in the Asian subpopulation from CheckMate 227.


      Method:
      Patients with chemotherapy-na

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.